Skip to main
LXRX
LXRX logo

Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target

Lexicon Pharmaceuticals (LXRX) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 20%
Buy 10%
Hold 50%
Sell 20%
Strong Sell 0%

Bulls say

Lexicon Pharmaceuticals Inc has reported favorable topline results from the Phase 2b dose-optimization PROGRESS clinical trial for its drug candidate pilavapadin (LX9211), which addresses diabetic peripheral neuropathic pain (DPNP), indicating a promising path forward for this treatment. The company is also experiencing strong partnership interest due to the high potential of pilavapadin, with an estimated 9 million diagnosed patients in the U.S. alone, suggesting a significant addressable market. Additionally, Lexicon's strategy to enhance market penetration for its therapies related to heart failure, hypertrophic cardiomyopathy, and DPNP, combined with the potential of its earlier-stage asset LX9851, supports a positive outlook for the company's future growth prospects.

Bears say

Lexicon Pharmaceuticals faces a negative outlook primarily due to disappointing clinical trial results, particularly regarding the 20 mg dose of RELIEF DPN-1, which failed to demonstrate statistical significance against placebo despite showing some improvement. Investor sentiment has been adversely affected by concerns over higher dropout rates and tolerability issues associated with the higher dose, leading to reduced confidence in the company's drug development pipeline. Additionally, potential challenges such as inconclusive clinical trials, difficulties in securing adequate funding, and the threat of dilutive capital raises present significant risks to the company’s valuation and future growth prospects.

Lexicon Pharmaceuticals (LXRX) has been analyzed by 10 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexicon Pharmaceuticals (LXRX) Forecast

Analysts have given Lexicon Pharmaceuticals (LXRX) a Hold based on their latest research and market trends.

According to 10 analysts, Lexicon Pharmaceuticals (LXRX) has a Hold consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexicon Pharmaceuticals (LXRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.